Chemotherapy-induced peripheral neuropathy common in early stage breast cancer
the ONA take:
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer and was strongly associated with docetaxel-based regimens, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
For the study, researchers from the Portuguese Institute of Oncology of Porto in Portugal sought to estimate the incidence of CIPN, identify factors associated with occurrence, and determine its impact on patient-reported outcomes.
Researchers enrolled 296 patients with incident breast cancer planning to receive chemotherapy. Patients were followed for 1 year.
Results showed that the cumulative incidence of CIPN in the first year after cancer diagnosis was 28.7% and more than 80% of participants were symptomatic 6 months after diagnosis.
The researchers found that patients who received docetaxel-based regimens were at a higher risk for developing CIPN, while alcohol consumption and diabetes were not significantly associated with CIPN.
“Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes,” the authors conclude.
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|